A Multinational, Multicenter, Masked, Randomized, Controlled Study to Assess The Safety and Efficacy of Lucinactant for Inhalation in Preterm Neonates 26 to 32 Weeks Gestational Age With Respiratory Distress Syndrome

Trial Profile

A Multinational, Multicenter, Masked, Randomized, Controlled Study to Assess The Safety and Efficacy of Lucinactant for Inhalation in Preterm Neonates 26 to 32 Weeks Gestational Age With Respiratory Distress Syndrome

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 07 Aug 2017

At a glance

  • Drugs Sinapultide (Primary)
  • Indications Respiratory distress syndrome
  • Focus Therapeutic Use
  • Sponsors Windtree Therapeutics
  • Most Recent Events

    • 04 Aug 2017 Planned number of patients changed from 240 to 320.
    • 29 Jun 2017 According to a Windtree Therapeutics media release, results of this trial will be discussed in a conference call and webcast.
    • 29 Jun 2017 According to a Windtree Therapeutics media release, this trial was was supported by a Fast Track Small Business Innovation Research (SBIR) grant from the National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Health (NIH).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top